Skip to main content
Premium Trial:

Request an Annual Quote

Alveo Technologies Receives CE Mark for COVID-19 Test

NEW YORK – Alveo Technologies said this week that it has received the CE mark for its Be.well COVID-19 Flex Test.

The test is for use with the firm's Be.well isothermal nucleic acid amplification platform and will be available soon in the UK and other parts of Europe, the Alameda, California-based company said, adding that it plans to submit the test to the US Food and Drug Administration for Emergency Use Authorization. Alveo was also named one of 20 finalists by the Xprize in December in a $6 million competition to develop rapid tests for detecting SARS-CoV-2.

The Be.well platform is being developed for use at home for the detection of infectious diseases with results available in 30 minutes, according to Alveo's website. Along with COVID-19, the firm is developing tests for the flu and respiratory syncytial virus for use with the Be.well platform.

Prior to the coronavirus pandemic, Alveo said that it planned to commercialize its infectious disease diagnostic platform, which is capable of detecting multiple viral pathogens at a low cost, for the point-of-care testing market.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.